Aimovig ® was discontinued in many of the reported cases. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Many of the patients had pre-existing hypertension or risk factors for hypertension. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig ® in the postmarketing setting. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications. Monitor patients treated with Aimovig ® for severe constipation and manage as clinically appropriate. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies. Aimovig ® was discontinued in most reported cases. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. There were cases that required hospitalization, including cases where surgery was necessary. If a serious or severe reaction occurs, discontinue Aimovig ® and initiate appropriate therapy.Ĭonstipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig ® in the postmarketing setting. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig ® in post marketing experience. Reactions have included anaphylaxis and angioedema. Important Safety InformationĬontraindication: Aimovig ® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Īimovig ® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults. Please see the full Terms and Conditions at. Please ask your Aimovig Ally™ representative to help you understand eligibility for the Aimovig ® Copay Card, and whether your particular insurance coverage is likely to result in your reaching the Maximum Monthly Benefit, the Maximum Annual Program Benefit, or your Patient Total Program Benefit, by calling 1-833-AIMOVIG (83). Whether you are eligible to receive the Maximum Monthly Benefit, Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Aimovig ® Copay Card benefits, Amgen has the right to reduce or eliminate those benefits. The Aimovig ® Copay Card provides support up to the Maximum Monthly Benefit, the Maximum Annual Program Benefit and/or Patient Total Program Benefit.Offer is subject to change or discontinuation without notice.The program provides assistance up to a Maximum Monthly Benefit except that the Maximum Monthly Benefit will not apply to the first 2 uses of the Aimovig ® Copay Card for Aimovig ® in any given calendar year.Patients are responsible for all amounts that exceed these limits. Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient up to a Maximum Monthly Benefit, a Maximum Annual Program Benefit and/or the Patient Total Program Benefit. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. With the Aimovig ® Copay Card, a commercially insured patient who meets eligibility criteria may pay as little as a $5 copay per month for their Aimovig ® monthly out-of-pocket costs.It is not valid for cash-paying patients or where prohibited by law. The program is not valid for patients whose Aimovig ® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. The Aimovig ® Copay Card is open to patients with commercial insurance, regardless of financial need.The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.Īs further described in the full terms and conditions, in general: It is important that every patient read and understand the full Aimovig ® (erenumab-aooe) Copay Card Terms and Conditions.
0 Comments
Leave a Reply. |